8-K: Harrow Reports Record 2025 Revenue, Strong 2026 Outlook

Harrow, Inc. announced record fourth quarter and full-year 2025 financial results, driven by strong growth in key ophthalmic products and provided optimistic 2026 financial guidance.

Summary

• Harrow achieved record quarterly revenue of $89.1 million in Q4 2025, a 33% increase over the prior-year period.
• Full-year 2025 revenue reached $272.3 million, marking a 36% increase compared to 2024.
• GAAP net income for Q4 2025 was $6.6 million, while the full-year 2025 resulted in a net loss of $5.1 million.
• Adjusted EBITDA was $24.2 million in Q4 2025 and $61.9 million for the full-year 2025.
• The company generated $43.9 million in operating cash flow in 2025, a significant improvement from $(22.2) million used in operations in 2024.
• Cash and cash equivalents stood at $72.9 million as of December 31, 2025.
• VEVYE revenue grew to $25.9 million in Q4 2025 and $88.7 million for the full-year 2025, representing increases of 62% and 216% respectively.
• IHEEZO revenue increased to $35.9 million in Q4 2025 and $81.3 million for the full-year 2025, up 57% and 65% respectively.
• TRIESENCE recorded its highest quarterly revenue since relaunch at $5.1 million in Q4 2025.
• Harrow provided full-year 2026 revenue guidance of $350 million to $365 million and Adjusted EBITDA guidance of $80 million to $100 million.
• Strategic initiatives for 2026 include doubling the VEVYE and TRIESENCE sales teams and expanding IHEEZO into office-based settings.
• The company expects to launch BYOOVIZ (LUCENTIS biosimilar) mid-year 2026 and OPUVIZ (EYLEA biosimilar) in January 2027.
• Compounded product revenue is projected to decline by approximately 10-20% in 2026 as the company shifts towards FDA-approved branded products.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to strong financial performance, significant cash flow generation, robust growth in key products, and clear strategic plans for future expansion and product launches, despite some near-term headwinds for IHEEZO and compounded products.

Positives

• Record quarterly revenue of $89.1 million in Q4 2025, a 33% increase year-over-year.
• Record full-year revenue of $272.3 million in 2025, a 36% increase over 2024.
• Significant turnaround in operating cash flow, generating $43.9 million in 2025 compared to $(22.2) million used in 2024.
• Strong growth in key products: VEVYE revenue increased 216% for full-year 2025 to $88.7 million, and IHEEZO revenue increased 65% for full-year 2025 to $81.3 million.
• TRIESENCE achieved its highest quarterly revenue since relaunch at $5.1 million in Q4 2025, with nearly half of the unit volume from new accounts.
• Positive 2026 financial guidance projecting revenue of $350 million to $365 million and Adjusted EBITDA of $80 million to $100 million.
• Strategic expansion plans include doubling VEVYE and TRIESENCE sales teams and expanding IHEEZO into the office-based setting.
• Clear pathway for biosimilar launches with BYOOVIZ expected mid-2026 and OPUVIZ in January 2027.
• Advancement of late-stage development pipeline assets like G-MELT and YOCHIL, with high commercial expectations.
• Resolution of a one-time inventory shortage of compounded products, with normalization expected by the end of Q1 2026.

Negatives

• Full-year 2025 GAAP net loss of $5.1 million, despite a profitable fourth quarter.
• Expected softer IHEEZO revenue in Q1 and part of Q2 2026 due to elevated customer stocking in Q4 2025 and the conclusion of pass-through payment status in the ASC setting.
• Anticipated decline of approximately 10-20% in compounded revenue for full-year 2026 as the company shifts to branded products.
• Increased Selling, General and Administrative (SG&A) costs to $152.9 million in 2025 from $129.1 million in 2024, driven by headcount and commercial activities.
• Increased Research and Development (R&D) expenses to $20.9 million in 2025 from $12.2 million in 2024, including $8.5 million for acquired in-process R&D.

Risks

• Risks related to liquidity or results of operations.
• Ability to successfully implement the business plan, develop and commercialize products, product candidates, and proprietary formulations in a timely manner or at all.
• Ability to identify and acquire additional products, manage pharmacy operations, service debt, and obtain necessary financing.
• Challenges in recruiting and retaining qualified personnel and managing any growth experienced.
• Risks associated with successfully realizing the benefits of previous acquisitions and any future acquisitions or collaborative arrangements.
• Competition from pharmaceutical companies, outsourcing facilities, and pharmacies.
• General economic and business conditions, including inflation and supply chain challenges.
• Regulatory and legal risks and uncertainties related to pharmacy operations and the pharmaceutical business, including ongoing communications with the U.S. Food and Drug Administration (FDA) regarding compliance and quality plans at the New Jersey outsourcing facility.
• Risks concerning physician interest in and market acceptance of current and any future formulations and compounding pharmacies generally.

Future Outlook

Harrow projects full-year 2026 revenue between $350 million and $365 million, with Adjusted EBITDA of $80 million to $100 million, expecting a stronger second half of the year. The company aims for over $250 million in quarterly revenue by the end of 2027 and plans to further leverage its commercial platform by launching late-stage assets like G-MELT and YOCHIL starting in 2028.

Management Comments

• "Last year was a defining year for Harrow, with revenue up 36% for the year and a record fourth quarter that reflected both accelerating demand and improving operating leverage, especially in terms of generating operating cash flow." Mark L. Baum, Chief Executive Officer.
• "Our key products are still in the early stages of launch, and each is gaining significant commercial traction." Mark L. Baum, Chief Executive Officer.
• "As we enter 2026, we are building on that momentum across the business: doubling the VEVYE and TRIESENCE sales teams, expanding IHEEZO into the office-based setting, advancing our development pipeline, and operating with greater alignment as One Harrow." Mark L. Baum, Chief Executive Officer.
• "I also believe we are going to provide positive surprises this year (and next) with a few products in our portfolio that haven't received much attention." Mark L. Baum, Chief Executive Officer.
• "With multiple growth drivers gaining traction and a larger commercial footprint coming online, I have increasing confidence in our ability to accelerate performance through 2026, to remain on track toward our goal of over $250 million in quarterly revenue by the end of 2027." Mark L. Baum, Chief Executive Officer.
• "Greater clarity in our financial guidance is an area where we owe it to Harrow stockholders to make improvements. Our new approach, while perhaps more conservative, will focus on greater transparency and structure. Our objective going forward is clear: to meet and beat expectations." Mark L. Baum, Chief Executive Officer.
• "If you are considering investing in Harrow today, my view is simple: take a long-term perspective. Our history suggests that patient stockholders who give us time to execute, measured in years, not months or quarters, have been richly rewarded." Mark L. Baum, Chief Executive Officer.
• "As someone committed to improving the standard of care in critical areas with unmet needs, there hasn't been a single Harrow product that I've been this excited about. We are talking about reducing or eliminating opioid exposures in tens of millions of procedures that too often use opioids for sedation and anxiety management. Once approved, I believe G-MELT will eventually be our largest product by revenue..." Mark L. Baum, Chief Executive Officer.

Industry Context

StockSavvy.ai notes that Harrow's strategic focus on expanding its commercial footprint for key ophthalmic products and its pipeline of biosimilars and novel drug candidates aligns with the growing demand for specialized treatments in the ophthalmic market. The company's emphasis on developing opioid-free surgical solutions, such as G-MELT, addresses a significant public health concern and positions it to capture market share in pain and anxiety management for various procedures.

Comparison to Industry Standards

• VEVYE's average refill rate of approximately 9 refills per year for covered patients is described as 'best-in-class in the dry eye disease market,' indicating superior patient persistence compared to competitors.
• IHEEZO is highlighted as the 'only FDA-approved ocular anesthetic in the U.S. with an FDA-approval supported by ophthalmic surgical clinical data,' providing a unique competitive advantage in the ophthalmic anesthesia market.
• TRIESENCE boasts a reimbursement rate of better than 90% and patient out-of-pocket expenses reported to be the lowest among ophthalmic injectable steroids, suggesting a highly favorable market access profile.
• A Market Scope survey indicating nearly 90% of U.S. cataract surgeons expressed interest in dropless cataract surgery validates TRIESENCE's potential to address a significant unmet need and simplify perioperative care.
• The G-MELT program, aiming to reduce or eliminate opioid exposures in tens of millions of procedures, leverages the success of a similar compounded version already used in over 1 million U.S. cataract surgeries, demonstrating a proven market acceptance for non-opioid procedural comfort.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, robust growth in key products, positive 2026 guidance, and a clear long-term growth strategy, with management emphasizing that patient stockholders have been 'richly rewarded'.
• Employees: Positive impact through planned expansion of sales teams for VEVYE and TRIESENCE, and overall company growth, suggesting increased hiring and career opportunities.
• Customers (Eye Care Professionals): Positive impact through an expanded portfolio of FDA-approved ophthalmic solutions, improved access, affordability, and innovative solutions for simplified perioperative care (e.g., TRIESENCE, G-MELT).
• Patients: Positive impact through expanded access to safe, effective, and affordable ophthalmic disease management solutions, including new treatments for dry eye and the development of opioid-free procedural comfort options like G-MELT.

Next Steps

• Double the VEVYE and TRIESENCE sales teams by Memorial Day.
• Expand IHEEZO into the office-based setting for other reimbursed procedures.
• Advance the development pipeline, including G-MELT and YOCHIL.
• Present Dr. Sabin Dang's abstract on IHEEZO in IVI protocol at the American Society of Retinal Specialists (ASRS) meeting in July.
• Expect data from the QUELL study for IHEEZO in the fourth quarter of 2026.
• Launch BYOOVIZ, a LUCENTIS referenced biosimilar, mid-year 2026.
• Launch BYQLOVI in the second quarter of 2026.
• Read out a seminal supportive study for an underappreciated specialty product in the fourth quarter of 2026.
• Complete remaining ancillary studies for the G-MELT NDA later this year and file the NDA as soon as practicable.
• Finalize the clinical development plan for YOCHIL with the FDA before the end of the third quarter and file its NDA around the same time as the G-MELT NDA.
• Launch OPUVIZ, an EYLEA biosimilar, in January 2027.
• Target the launch of a TRIESENCE pre-filled syringe in the 2028 timeframe.
• Begin launching late-stage, large market assets in development, like G-MELT and YOCHIL, starting in 2028.

Key Dates

Recommendation

The company delivered record revenues and a significant turnaround in operating cash flow in 2025, coupled with robust growth in its core branded products. The 2026 guidance projects substantial continued growth in both revenue and Adjusted EBITDA, supported by strategic investments in sales force expansion and upcoming biosimilar launches. The long-term pipeline, particularly G-MELT and YOCHIL, offers significant future growth potential in large, underserved markets. While there are some near-term headwinds for IHEEZO and compounded products, the overall trajectory and strategic execution indicate strong upside for long-term investors.

Keywords

Ophthalmic, Pharmaceuticals, Dry Eye Disease, Cataract Surgery, Anesthesia, Biosimilar, VEVYE, IHEEZO, TRIESENCE, G-MELT, YOCHIL, Financial Results, Revenue Growth, Adjusted EBITDA, SEC Filing, Drug Development, Commercialization, HROW